Genprex Announces First Patient Dosed in Phase I/II Acclaim-1 Clinical Trial of REQORSA^™ Immunogene Therapy in Combination with Tagrisso^® to Treat Non-Small Cell Lung Cancer

Genprex, Inc. announced that the first patient was dosed in the Acclaim-1 clinical trial, an open-label, multi-center Phase I/II clinical trial evaluating REQORSA™ Immunogene Therapy, in combination with Tagrisso® (osimertinib) in patients with late-stage NSCLC.